Market Overview

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Share:
Related RGEN
15 Stocks Which Rallied Four Days, Then Sold Off Yesterday
Mid-Afternoon Market Update: Stage Stores Drops On Downbeat Results; Urban Outfitters Shares Surge
Related PFE
The Market In 5 Minutes: No Interest Rate Hike...Yet
Can You Guess This Chart?
Amgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw Interest (Investor's Business Daily)

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Posted-In: News FDA

 

Related Articles (RGEN + PFE)

View Comments and Join the Discussion!